Oct 15, 2024 | Uncategorized
MAT2A and PRMT5 have emerged as critical cancer targets, with about 15% of all tumors showing MTAP depletion—a number that can increase to 30% after chemotherapy. Despite their promise, developing MAT2A inhibitors has proven challenging for many companies, with...
